This study offers an emerging BRD4-mediated epigenetic pathway, which determines mesenchymal stem cell fate in glucocorticoid-induced osteoporotic skeleton and fatty marrow, and highlights the perspective of BRD4 inhibitor protection against glucocorticoid overmedication-mediated bone disorders. Here, BRD4 is linked to bone disorder.